Literature DB >> 24622375

Ipilimumab-induced autoimmune adrenalitis.

Le Min1, Nageatte Ibrahim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24622375      PMCID： PMC4106239          DOI： 10.1016/S2213-8587(13)70031-7

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  29 in total

Review 1.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

Review 2.  Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.

Authors:  Ali Pourvaziri; Anushri Parakh; Pierpaolo Biondetti; Dushyant Sahani; Avinash Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 3.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

4.  Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.

Authors:  Virginie Grouthier; Bénédicte Lebrun-Vignes; Melissa Moey; Douglas B Johnson; Javid J Moslehi; Joe-Elie Salem; Anne Bachelot
Journal:  Oncologist       Date:  2020-05-17

5.  Humanized mice as a model for aberrant responses in human T cell immunotherapy.

Authors:  Nalini K Vudattu; Frank Waldron-Lynch; Lucy A Truman; Songyan Deng; Paula Preston-Hurlburt; Richard Torres; Maurice T Raycroft; Mark J Mamula; Kevan C Herold
Journal:  J Immunol       Date:  2014-06-18       Impact factor: 5.422

Review 6.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 7.  Time to dissect the autoimmune etiology of cancer antibody immunotherapy.

Authors:  Michael Dougan; Massimo Pietropaolo
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 8.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 9.  Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies.

Authors:  Annu Susan George; Cornelius J Fernandez; Dilip Eapen; Joseph M Pappachan
Journal:  touchREV Endocrinol       Date:  2021-04-28

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.